More and more people are exploring medical marijuana, also called cannabis, as a treatment option for various chronic health conditions, including Parkinson’s disease. Several states have legalized medical cannabis, but because federal drug laws have prevented scientific investigations on cannabis and its components for many years, much is still unknown about its use for medical purposes. Patients have questions about it, and physicians are still feeling their way through the landscape of medicinal cannabis use. Dr. Danny Bega of Northwestern University’s Parkinson’s Disease and Movement Disorders Center in Chicago, a Parkinson’s Foundation Center of Excellence, sheds light on some of the issues and concerns surrounding the use of medicinal cannabis.
- Marijuana and PD: What Do We Really Know? (webinar)
- Research Roundup: Medical Marijuana and Parkinson’s Disease at a Glance
- What’s Hot in PD? Everything You Need to Know About Medical Marijuana and Parkinson’s Disease
For all of our Substantial Matters podcast episodes, visit parkinson.org/podcast.
About This Episode
Released: April 10, 2018
Danny Bega, MD, MSCI
Dr. Bega is a fellowship trained, board-certified, movement disorders neurologist at the Northwestern University Feinberg School of Medicine. He has completed clinical training in neurology at Harvard’s Massachusetts General Hospital and Brigham & Women’s Hospital. Dr. Bega has expertise in the care and management of patients with a variety of movement disorders including Parkinson’s disease, and is the director of the Northwestern Huntington’s disease and Wilson’s disease clinics. He has completed master’s level training in clinical investigations through the Northwestern Graduate School and is involved in several industry sponsored trials. His primary area of interest is the study of alternative and non-pharmacologic interventions in movement disorders and their impact on quality of life.